Presentation is loading. Please wait.

Presentation is loading. Please wait.

Study Design  ADA, adalimumab; DL, drug levels; FCP, faecal calprotectin; pCCR, patient-reported continuous clinical response; PRO, patient-reported outcomes.

Similar presentations


Presentation on theme: "Study Design  ADA, adalimumab; DL, drug levels; FCP, faecal calprotectin; pCCR, patient-reported continuous clinical response; PRO, patient-reported outcomes."— Presentation transcript:

1 Study Design  ADA, adalimumab; DL, drug levels; FCP, faecal calprotectin; pCCR, patient-reported continuous clinical response; PRO, patient-reported outcomes. Study Design  ADA, adalimumab; DL, drug levels; FCP, faecal calprotectin; pCCR, patient-reported continuous clinical response; PRO, patient-reported outcomes. Juliette Sheridan et al. BMJ Open Gastroenterol 2018;5:e000174 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) All rights reserved. No commercial use is permitted unless otherwise expressly granted.


Download ppt "Study Design  ADA, adalimumab; DL, drug levels; FCP, faecal calprotectin; pCCR, patient-reported continuous clinical response; PRO, patient-reported outcomes."

Similar presentations


Ads by Google